Recliner,US,$95,/feodatory242741.html,Home & Garden , Furniture , Chairs,bgti.in,Gray,Fabric,Dark,vidaXL vidaXL Recliner Dark Gray Max 73% OFF Fabric US $95 vidaXL Recliner Dark Gray Fabric US Home & Garden Furniture Chairs $95 vidaXL Recliner Dark Gray Fabric US Home & Garden Furniture Chairs Recliner,US,$95,/feodatory242741.html,Home & Garden , Furniture , Chairs,bgti.in,Gray,Fabric,Dark,vidaXL vidaXL Recliner Dark Gray Max 73% OFF Fabric US

vidaXL Recliner Dark Gray Max 73% OFF Fabric US Japan Maker New

vidaXL Recliner Dark Gray Fabric US

$95

vidaXL Recliner Dark Gray Fabric US

|||

Item specifics

Condition:
New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is ...
Brand:
vidaXL
Item Height:
As Description
Item Width:
As Description
Colour:
Grey
Item Length:
As Description
Type:
Does not apply
Product:
As Description
Style:
Does not apply
Connectivity:
Does not apply
Designer/Brand:
Does not apply
Compatible Mattress Size:
Does not apply
Fit:
Does not apply
Chest Size:
Does not apply
Model:
As Description
Set Includes:
Does not apply
Number of Items in Set:
Does not apply
Frame Material:
Does not apply
Manufacturer Part Number:
Does not apply
UPC:
Does not apply
EAN:
Does not apply








vidaXL Recliner Dark Gray Fabric US

Intro Pullout Text Widget

is a leading rheumatology journal from BMJ and EULAR, publishing original research, reviews and recommendations

Impact Factor: 19.103
Citescore: 28.7
All metrics >> 

Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal covering all aspects of rheumatology, which includes the full spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research, including the most important recommendations for the management of various conditions.

ARD is an official journal of EULAR.

Free NEW VASELINE Intensive Care Moisturizing Bath Beads Gentle Breez are provided for selected research articles and all Latvia 1937 Gaujas Lici Postcard w/Riga 'H' Cancel. You can keep up with the latest news via Twitter and Facebook.

Listen to the ARD podcast and subscribe in all podcast platforms, including Apple PodcastGoogle PodcastsStitcher and Spotify.

Editor-in-Chief: Professor Josef Smolen, Medical University of Vienna, Austria
Editorial team

ARD is a Plan S compliant Transformative Journal.

Latest Content

Authors

Annals of the Rheumatic Diseases considers unsolicited submissions of a variety of article types, including original research articles (extended and concise reports), viewpoints, and letters to the Editor.
 
The Author Information section provides general guidelines and requirements for specific article types.
 
Information is also provided on editorial policies and open access.

Free Lay Summaries

Are you looking for the latest rheumatology research findings presented in an easily accessible format to share with patients, carers or colleagues?

 

ARD provides free lay summaries for selected research articles and all EULAR recommendations.

 

These aim to clearly explain the results of the research studies as well as any implications for treatment of the specific condition. The summaries are written in plain language in a consistently structured format and checked for accuracy and readability by experts and patient representatives.

 

EULAR Recommendations

The EULAR Standing Committees regularly establish and publish recommendations for the treatment of various rheumatic disorders. Each of these recommendations is developed by a group of specialists in their field.

 

All EULAR recommendations are free to access

 

Each recommendation also has an accompanying Yu-Gi-Oh Dark Lord Deck 61 Cards Dark Lord Deck * 160 Yugioh, which is also free to access.

Video Abstract

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE

To cite: Vital EM, Merrill JT, Morand EF, et al. Ann Rheum Dis. doi: 10.1136/annrheumdis-2021-221425

Read the full article here: link
Objective: To characterise the efficacy and safety of anifrolumab in patients with systemic lupus erythematosus (SLE) according to interferon gene signature (IFNGS), demographic and clinical subgroups.

Conclusions: Overall, this study supports the consistent efficacy and safety of anifrolumab across a range of patients with moderate-to-severe SLE. In a few subgroups, small sample sizes limited conclusions from being drawn regarding the treatment benefit with
anifrolumab.

Podcasts